Grifols (NASDAQ:GRFS) Sets New 52-Week High - Should You Buy?

Key Points

• Grifols' stock reached a new 52-week high of $10.50, reflecting a significant increase from its previous close of $10.09, with over 3.6 million shares traded.
• Several analysts have updated their ratings, with Wall Street Zen upgrading Grifols to a "strong-buy" and JPMorgan raising its price target to $10.30.
• Institutional investors have been actively modifying their stakes, with notable increases in holdings by firms like Sequoia Financial Advisors and GAMMA Investing LLC.

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) reached a new 52-week high on Wednesday . The company traded as high as $10.50 and last traded at $10.50, with a volume of 3647605 shares trading hands. The stock had previously closed at $10.09.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Wall Street Zen upgraded shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th.

Grifols Stock Performance

The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.97 and a current ratio of 2.64. The stock's 50-day moving average is $9.19 and its 200 day moving average is $8.03. The firm has a market cap of $7.41 billion, a P/E ratio of 9.21, a PEG ratio of 0.37 and a beta of 0.56.

Grifols Dividend Announcement

The company also recently disclosed a -- dividend, which will be paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th will be given a $0.1404 dividend. The ex-dividend date is Tuesday, August 12th.

Hedge Funds Weigh In On Grifols

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in shares of Grifols in the first quarter valued at about $28,000. Tower Research Capital LLC TRC lifted its holdings in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares in the last quarter. First Trust Advisors LP bought a new stake in shares of Grifols in the fourth quarter valued at about $75,000. Ballentine Partners LLC bought a new stake in shares of Grifols in the first quarter valued at about $77,000. Finally, Principal Street Partners LLC bought a new stake in shares of Grifols in the fourth quarter valued at about $84,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.